


## Supplementary Material


**Supplementary Table 1. Prevalence of side effects in participants (n=90) after the second dose of Comirnaty vaccine and severity score**

Side effects	% of participants			
	Any score	Score 1*	Score 2	Score 3
Injection site pain or swelling	84	56	26	3
Injection site redness	20	18	2	0
Injection site pruritus	18	14	3	0
Headache	42	12	22	8
Fatigue	64	20	31	13
Malaise	50	13	24	12
Chills	41	14	22	4
Fever	34	12	17	6
Myalgia	34	10	20	4
Arthralgia	21	7	12	2
Pain in extremity	13	3	8	2
Insomnia	12	6	7	0
Nausea	11	6	4	1
Diarrhea	3	3	0	0
Lymphadenopathy	8	4	3	0
Facial sensitivity disorder	2	2	0	0
Hypersensitivity/allergic reaction	0	0	0	0


\*Score: 1- mild symptoms that did not disturb daily life; 2- moderate symptoms that somewhat disturbed the activities of daily living; 3- symptoms that last days and/or caused absence from work




**Supplemental Figure 1. Line chart to show the results of S-RBD IgG antibody levels and dynamics between the sample values before the vaccination (B1D), before the second dose (B2D), and 1 (1wA2D), 6 (6wA2D) and 12 (12wA2D) weeks after the second dose.**




**Supplementary Figure 2. Correlations between age, S-RBD IgG levels and ACE2-trimeric S blocking capacity.** Higher size and intensity of dots indicates stronger correlation; Blue dots – positive correlation; Red dots – negative correlation; Boxed dots – statistically significant correlation ( $p < 0.05$ ). W - Wuhan SARS-CoV-2 variant; U – UK variant (B.1.1.7); S – South African variant (B.1.351); B – Brazilian variant (P.1)



**Supplementary Figure 3. S-RBD IgG (AU/ml) and ACE2-trimeric S blocking capacity (relative OD) correlation blots at timepoints 1wA2A and 12wA2D. W - Wuhan SARS-CoV-2 variant; U – UK variant (B.1.1.7); S – South African variant (B.1.351); B – Brazilian variant (P.1)**



**Supplementary Figure 4. S-RBD IgG levels among persons >40 and ≥40 years old.** The group-wise box-plot comparisons of the S-RBD IgG levels in <40 and ≥40 years old vaccinated individuals after the first vaccine dose, and 1, 6, 12 weeks after the second vaccine dose (two-tailed t-test, \*\*  $p < 0.001$ , \*  $p < 0.05$ ).



**Supplementary Figure 5. Correlations between age, S-RBD IgG levels and vaccine side-effects.** Higher size and intensity of dots indicates stronger correlation; Blue dots – positive correlation; Red dots – negative correlation; Boxed dots – statistically significant correlation ( $p < 0.05$ ). Side effects: S1 - Injection site pain or swelling; S2 - Injection site redness; S3 - Injection site pruritus; S4 – Headache; S5 – Fatigue; S6 – Malaise; S7 – Chills; S8 – Fever; S9 – Myalgia; S10 – Arthralgia; S11 - Pain in extremity; S12 – Insomnia; S13 – Nausea; S14 – Diarrhea; S15 – Lymphadenopathy; S16 - Facial sensitivity disorder; S17 - Hypersensitivity/allergic reaction; S\_tot – Total side effects score